Dermatosis in physicians and nurses working during the COVID-19 pandemic in two basic hospitals
DOI:
https://doi.org/10.35381/s.v.v6i2.2086Keywords:
Dermatología, teledermatología, enfermedades de la piel. (Fuente, DeCS).Abstract
Objective: To determine the prevalence of dermatologic conditions and characteristics of lesions in medical and nursing personnel working in two basic hospitals in the city of Riobamba, Ecuador, during the COVID-19 pandemic. Methods: Descriptive observational study. Results: Among the health personnel under study there is no statistical evidence to determine the existence of pre-existing diseases, according to the position, χ2 (1, N=50) = 0.123, p<.05. Conclusion: The world repercussion of the COVID-19 pandemic is of high dimensions and represents the most dangerous known threat in a respiratory virus, since the H1N1 influenza pandemic; therefore it is a great alert for occupational health.
Downloads
References
Blegvad C, Skov L, Zachariae C. Ixekizumab for the treatment of psoriasis: an update on new data since first approval. Expert Rev Clin Immunol. 2019;15(2):111-121. doi:10.1080/1744666X.2019.1559730
Vu TT, Gooderham M, Papp K. Ixekizumab for treatment of adults with moderate-to-severe plaque psoriasis and psoriatic arthritis. Expert Rev Clin Pharmacol. 2016;9(11):1423-1433. doi:10.1080/17512433.2016.1242409
Henderson Berg MH, Carrasco D. Injection Site Reactions to Biologic Agents Used in Psoriasis and Psoriatic Arthritis. J Drugs Dermatol. 2017;16(7):695-698. Thomaidou E, Ramot Y. Injection site reactions with the use of biological agents. Dermatol Ther. 2019;32(2):e12817. doi:10.1111/dth.12817
Craig S, Warren RB. Ixekizumab for the treatment of psoriasis: up-to-date. Expert Opin Biol Ther. 2020;20(6):549-557. doi:10.1080/14712598.2020.1729736
Villar Vinuesa R., Ramada Rodilla J.M., Serra Pujadas C. Papel del médico del trabajo en la identificación y reconocimiento oficial de las dermatosis profesionales [Role of the occupational physician in the identification and official recognition of occupational dermatoses]. Arch Prev Riesgos Labor [Internet]. 2017; 20(4): 214-219.
TZANCK A, SIDI E. Dermites allergiques; statistique des dermatoses allergiques étudiées au laboratoire des tests de l'Hopital Saint-Louis durant les années 1949, 1950, 1951 [Allergic dermatitis; statistics of allergic dermatosis studied in the laboratory of tests of St. Louis Hospital, 1949-51]. Sem Hop. 1952;28(81):3267-3269.
Arellano Ocampo F. Dermatósis alérgicas profesionales [Professional allergic dermatosis]. Alergia. 1977;24(1):11-22.
Guan WJ, Zhong NS. Clinical Characteristics of Covid-19 in China. Reply. N Engl J Med. 2020;382(19):1861-1862. doi:10.1056/NEJMc2005203
Zavascki AP, Falci DR. Clinical Characteristics of Covid-19 in China. N Engl J Med. 2020;382(19):1859. doi:10.1056/NEJMc2005203
Rodriguez-Morales AJ, Gallego V, Escalera-Antezana JP, et al. COVID-19 in Latin America: The implications of the first confirmed case in Brazil. Travel Med Infect Dis. 2020;35:101613. doi:10.1016/j.tmaid.2020.101613
Guanche Garcell H. COVID-19. Un reto para los profesionales de la salud [COVID-19. A challenge for healthcare professionals]. Rev haban cienc méd [Internet]. 2020;19(2): [aprox. 0 p.]. Disponible en: http://www.revhabanera.sld.cu/index.php/rhab/article/view/3284
Guertler A, Moellhoff N, Schenck TL, et al. Onset of occupational hand eczema among healthcare workers during the SARS-CoV-2 pandemic: Comparing a single surgical site with a COVID-19 intensive care unit. Contact Dermatitis. 2020;83(2):108-114. doi:10.1111/cod.13618
Brouder P. Reset redux: possible evolutionary pathways towards the transformation of tourism in a COVID-19 world, Tourism Geographies, 2020;22:3, 484-490, DOI: 10.1080/14616688.2020.1760928
Tisdell CA. Economic, social and political issues raised by the COVID-19 pandemic. Econ Anal Policy. 2020;68:17-28. doi:10.1016/j.eap.2020.08.002
Ali I. Impact of COVID-19 on vaccination programs: adverse or positive?. Hum Vaccin Immunother. 2020;16(11):2594-2600. doi:10.1080/21645515.2020.1787065
Published
How to Cite
Issue
Section
License
CC BY-NC-SA : Esta licencia permite a los reutilizadores distribuir, remezclar, adaptar y construir sobre el material en cualquier medio o formato solo con fines no comerciales, y solo siempre y cuando se dé la atribución al creador. Si remezcla, adapta o construye sobre el material, debe licenciar el material modificado bajo términos idénticos.
OAI-PMH: https://fundacionkoinonia.com.ve/ojs/index.php/saludyvida/oai.
